About IRUBIS

Vision & Mission

Helping accelerate the development of life-saving medications to patients and
improving process efficiencies through bioprocess automatization.
  • 2017

    IRUBIS GmbH is founded and wins the Medical Valley Award. The team develops a silicon crystal for infrared spectroscopy.
  • 2018

    Technological proof of concept: Online monitoring of glucose with IRUBIS silicon crystal and a mid-infrared spectrometer.
  • 2019

    Our prototype is tested at biopharma companies.
  • 2020

    IRUBIS is one of the winners of the H2020 EIC Accelerator Pilot and uses this momentum and grant to develop Monipa and to validate prototype in the biopharma industry.
  • 2021

    Market entry with Monipa: Online monitoring in upstream bioprocessing of metabolite and nutrient concentration and for automated glucose control.
  • 2022

    IRUBIS, has raised EUR 2.8m in a seed financing round. The round was led by High-Tech Gründerfonds (HTGF), Verve Ventures and Ventura BioMed Investors with the participation of EIC Fund, the Initiative for Industrial Innovators and a number of business angels from the biotech industry or Munich startup scene.
  • 2023

    Released the new Monipa 1 with a modern and user-friendly design, delved into downstream applications, enhancing both innovation and functionality in the bioprocessing industry.
  • 2024

    IRUBIS has successfully closed the pre-series A funding round, led by BioProcess360 Partners, with support from our valued investors, including High-Tech Gründerfonds, Verve Ventures, Ventura BioMed Investors, RoBet KG, and esteemed business angels Matthias Arnold and Dr. Christoph Bremus. Expanded applications of the new Monipa 1 in UF/DF and other downstream processing steps.

OUR GRANTS & AWARDS

OUR INVESTORS